Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.
Jean-Yves BlayQuentin DevinFlorence DuffaudMaud ToulmondeNelly FirminOlivier CollardEmmanuelle BompasBenjamin VerretIsabelle Ray-CoquardSebastien SalasClemence HenonCharles HonoréMehdi BrahmiArmelle DufresneMarc PrachtAlice HervieuNicolas PenelFrancois BertucciMaria RiosEsma Saada-BouzidPauline SoibinetDavid PerolSylvie ChabaudAntoine ItalianoAxel Le CesnePublished in: The Lancet. Oncology (2024)
Centre Léon Bérard, INCa, CONTICANET, Ligue Contre le Cancer, and Novartis.